
|
•
|
Completed business combination with NewHold Investment Corp III (“SPAC”) on September 21, 2026 (the “Business Combination”); newcleo’s
ordinary shares and warrants commenced trading on the Nasdaq Global Select Market on September 22, 2026 under the symbols “NWCL” and “NWCLW,” respectively
|
|
•
|
The Business Combination generated gross proceeds of approximately $247 million, consisting of approximately $31 million released from the SPAC’s trust account and
$216 million from the PIPE financing
|
|
•
|
Raised approximately $18.7 million in additional financing unrelated to the Business Combination since May 2026, bringing total funds raised since newcleo’s founding to over $1 billion
|
|
•
|
Installed the main vessel and turbine for its PRECURSOR non-nuclear 10 MWt demonstration reactor at the ENEA Brasimone Research Center outside Bologna, Italy;
completion of construction for PRECURSOR is expected by the end of 2026, with at-scale validation of systems to commence thereafter
|
|
•
|
In partnership with Oklo, selected by the U.S. Department of Energy for advanced negotiations under the Surplus Plutonium Utilization Program
|
|
•
|
Submitted Regulatory Engagement Plans to the U.S. Nuclear Regulatory Commission for the Company’s LFR-AS-200 lead-cooled fast reactor and its planned U.S.
mixed-oxide (MOX) fuel fabrication facility
|
|
•
|
Received notice of an overall opinion of satisfactory compliance from the French Nuclear Safety and Radiation Protection Authority for the proposed safety features
for the Company’s planned MOX fuel fabrication facility in France
|
|
•
|
Announced the acquisition, subject to customary closing conditions, of Bonifait Pesage, a French manufacturer of nuclear-grade scales and precision industrial
weighing equipment, augmenting the Company’s vertically integrated capabilities
|
|
•
|
Announced the appointment of Jeffrey Lyash, a nuclear industry veteran and former head of the Tennessee Valley Authority, as Chairman of the Board of Directors
|
|
•
|
Announced the appointment of William D. Magwood as Vice-Chairman of newcleo’s Board of Directors, effective January 1, 2027
|
|
•
|
Announced the hiring of Dustin Greenwood as Vice President of U.S. Operations and Travis Chapman as Director of U.S. Regulatory Affairs and Licensing, strengthening
the Company’s growing U.S. team
|
|
•
|
Announced a partnership with SHINE to assess and jointly pursue opportunities relating to nuclear fuel recycling in the United States and European Union
|
|
•
|
On September 10, newcleo held an Analyst and Investor Day, a recording of which is available on newcleo’s website
|
|
•
|
Generated Revenue from Products and Services of approximately €19.4 million, an increase of approximately 46% over First Half 2025
|
|
•
|
Reported Net Loss of approximately €82.0 million, an increase of approximately 10% over First Half 2025
|
|
•
|
Reported Tangible Capital Expenditures of €25.3 million, an increase of 37% over First Half 2025
|
|
•
|
Reported Selling, General & Administrative expenses of €59.2 million, an approximately 21% increase over First Half 2025
|
|
•
|
Cash & Cash Equivalents as of June 30, 2026 stood at €66.5 million
|
|
•
|
Total ordinary shares outstanding as of the closing date of the Business Combination stood at 281,534,950
|
|
•
|
As of September 30, 2026, preliminary, unaudited Cash & Cash Equivalents for the Company stood at approximately €233 million
|



|
(Amounts in thousands)
|
For the Six Months Ended
|
|||
|
6/30/2026
|
6/30/2025
|
|||
|
Revenue from Products and Services
|
€ 19,429
|
€ 13,347
|
||
|
Gross Profit
|
6,130
|
4,154
|
||
|
Other Income
|
6,554
|
4,763
|
||
|
Net Loss
|
81,981
|
74,293
|
||
|
Capital Expenditures
|
26,970
|
19,000
|
||
|
Cash & Cash Equivalents (end of period)
|
66,540
|
131,896
|
||


|
For the six months ended June 30,
|
For the six months ended June 30 2026
|
||
|
2026
|
2025
|
||
|
|
(in thousands of euros unless otherwise stated)
|
Convenience translation into US dollars*
|
|
|
Revenue from Products and Services
|
19,429
|
13,347
|
22,149
|
|
Cost of sales
|
(13,299)
|
(9,193)
|
(15,161)
|
|
Gross profit
|
6,130
|
4,154
|
6,988
|
|
|
|||
|
Other income
|
6,554
|
4,763
|
7,472
|
|
Research and development expenses
|
(34,629)
|
(35,450)
|
(39,477)
|
|
Selling, General and Administrative expenses
|
(59,170)
|
(48,932)
|
(67,454)
|
|
Operating loss
|
(81,115)
|
(75,465)
|
(92,471)
|
|
|
|||
|
Loss on disposal of assets
|
(9)
|
(3)
|
(10)
|
|
Finance income
|
353
|
1,581
|
402
|
|
Finance costs
|
(1,448)
|
(991)
|
(1,650)
|
|
Share of loss of associates
|
(83)
|
-
|
(95)
|
|
Loss before income tax
|
(82,302)
|
(74,878)
|
(93,824)
|
|
|
|||
|
Income tax benefit
|
321
|
585
|
366
|
|
Net loss
|
(81,981)
|
(74,293)
|
(93,458)
|
|
|
|||
|
Other comprehensive income (loss)
|
|||
|
Items that may be subsequently reclassified to profit or loss
|
|||
|
Currency translation differences
|
198
|
(144)
|
226
|
|
Other comprehensive income (loss), net of tax
|
198
|
(144)
|
226
|
|
|
-
|
||
|
Total comprehensive loss
|
(81,783)
|
(74,437)
|
(93,232)
|
|
Net loss attributable to:
|
|||
|
Owners of newcleo plc
|
(81,981)
|
(74,293)
|
(93,458)
|
|
Non-controlling interest
|
-
|
-
|
-
|
|
Total comprehensive loss attributable to:
|
|||
|
Owners of newcleo plc
|
(81,783)
|
(74,437)
|
(93,232)
|
|
Non-controlling interest
|
-
|
-
|
-
|
|
Net loss per share for loss attributable to the ordinary equity holders:
|
|||
|
Basic and diluted loss per share
|
(0.16)
|
(0.16)
|
(0.18)
|

|
June 30, 2026
|
December 31, 2025
|
June 30, 2026
|
|
|
|
(in thousands of euros unless otherwise stated)
|
Convenience translation into US dollars*
|
|
|
ASSETS
|
|
|
|
|
NON-CURRENT ASSETS
|
|||
|
Goodwill
|
37,281
|
37,281
|
42,500
|
|
Intangible assets, net
|
42,760
|
43,054
|
48,746
|
|
Property, plant and equipment, net
|
115,999
|
93,436
|
132,239
|
|
Right-of-use asset
|
17,665
|
18,521
|
20,138
|
|
Investments
|
76
|
75
|
87
|
|
Investments in associates
|
31,553
|
31,635
|
35,970
|
|
Other long-term receivables
|
34,871
|
35,207
|
39,753
|
|
Deferred tax assets
|
3,059
|
2,176
|
3,487
|
|
TOTAL NON-CURRENT ASSETS
|
283,264
|
261,385
|
322,920
|
|
|
|||
|
CURRENT ASSETS
|
|||
|
Inventories
|
4,843
|
5,057
|
5,521
|
|
Short-term investments
|
2,335
|
2,291
|
2,662
|
|
Trade receivable, contract and other assets, net
|
77,768
|
62,314
|
88,656
|
|
Cash and cash equivalents
|
66,540
|
105,270
|
75,856
|
|
TOTAL CURRENT ASSETS
|
151,486
|
174,932
|
172,695
|
|
TOTAL ASSETS
|
434,750
|
436,317
|
495,615
|
|
|
|||
|
NON-CURRENT LIABILITIES
|
|||
|
Provisions
|
4,094
|
4,170
|
4,667
|
|
Other liabilities
|
8,932
|
9,305
|
10,182
|
|
Lease liabilities
|
14,667
|
15,537
|
16,720
|
|
Borrowings
|
15,929
|
16,306
|
18,159
|
|
Deferred tax liabilities
|
4,430
|
4,244
|
5,050
|
|
TOTAL NON-CURRENT LIABILITIES
|
48,052
|
49,562
|
54,778
|
|
|
|||
|
CURRENT LIABILITIES
|
|||
|
Provisions
|
378
|
186
|
431
|
|
Trade and other payables
|
60,055
|
83,808
|
68,463
|
|
Lease liabilities
|
3,545
|
3,250
|
4,041
|
|
Borrowings
|
2,497
|
2,583
|
2,847
|
|
TOTAL CURRENT LIABILITIES
|
66,475
|
89,827
|
75,782
|
|
TOTAL LIABILITIES
|
114,527
|
139,389
|
130,560
|
|
EQUITY
|
|||
|
Share capital
|
5,046
|
4,739
|
5,752
|
|
Share premium
|
23,378
|
562,904
|
26,652
|
|
Other reserves
|
57,067
|
51,383
|
65,057
|
|
Retained earnings (accumulated deficits)
|
234,695
|
(324,123)
|
267,552
|
|
Equity attributable to owners of newcleo plc
|
320,186
|
294,903
|
365,013
|
|
Non-controlling interests
|
37
|
2,025
|
42
|
|
TOTAL EQUITY
|
320,223
|
296,928
|
365,055
|
|
TOTAL EQUITY AND LIABILITIES
|
434,750
|
436,317
|
495,615
|

|
For the six months ended June 30
|
For the six months ended June 30 2026
|
|||||
|
2026
|
2025
|
|||||
|
|
(in thousands of euros)
|
Conve-nience translation into US$*
|
||||
|
Cash flows from operating activities
|
|
|||||
|
Net loss
|
(81,981)
|
(74,293)
|
(93,458)
|
|||
|
Adjustments to reconcile net loss to net cash flows:
|
||||||
|
Loss from associates
|
83
|
-
|
95
|
|||
|
Finance income
|
(30)
|
(1,476)
|
(34)
|
|||
|
Finance costs
|
1,131
|
830
|
1,289
|
|||
|
Income tax benefit
|
(321)
|
(585)
|
(366)
|
|||
|
Depreciation of property, plant and equipment and right-of-use assets, amortization intangible assets and provisions
|
8,286
|
7,397
|
9,446
|
|||
|
Share-based payment expense
|
21,010
|
4,975
|
23,951
|
|||
|
Loss on disposals
|
9
|
4
|
10
|
|||
|
Other revenues and expenses without effect on cash flow
|
3
|
5
|
3
|
|||
|
Changes in working capital:
|
-
|
|||||
|
Decrease in inventory
|
214
|
94
|
244
|
|||
|
(Increase) in trade receivables, contract and other assets
|
(15,217)
|
(6,781)
|
(17,347)
|
|||
|
Increase (decrease) in trade and other payables
|
13,077
|
(2,428)
|
14,908
|
|||
|
Income taxes received
|
49
|
25
|
56
|
|||
|
Net cash flows used in operating activities
|
(53,687)
|
(72,233)
|
(61,203)
|
|||
|
|
||||||
|
Cash flows from investing activities
|
||||||
|
Acquisition of intangible assets
|
(1,642)
|
(458)
|
(1,872)
|
|||
|
Purchase of property, plant and equipment
|
(25,328)
|
(18,542)
|
(28,874)
|
|||
|
Proceeds from maturities of short-term investments
|
-
|
997
|
-
|
|||
|
Purchase of short-term investments
|
(41)
|
(160)
|
(47)
|
|||
|
Interest received from short-term investments
|
30
|
1,477
|
34
|
|||
|
Decrease (increase) in loans and deposits made
|
4
|
(2)
|
5
|
|||
|
Proceeds from sale of tangible and intangible assets
|
10
|
5
|
12
|
|||
|
Net cash flows used in investing activities
|
(26,967)
|
(16,683)
|
(30,742)
|
|||
|
|
||||||
|
Cash flows from financing activities
|
||||||
|
Proceeds from issues of shares
|
45,121
|
-
|
51,438
|
|||
|
Proceeds from issue of shares to non-controlling shareholders
|
-
|
31,637
|
-
|
|||
|
Repayments of borrowings and lease liabilities
|
(2,129)
|
(2,535)
|
(2,427)
|
|||
|
Interest expenses including interest on lease
|
(1,131)
|
(800)
|
(1,289)
|
|||
|
Net cash flows from financing activities
|
41,861
|
28,302
|
47,722
|
|||
|
|
||||||
|
Net decrease in cash and cash equivalents
|
(38,793)
|
(60,614)
|
(44,223)
|
|||
|
|
||||||
|
105,270
|
192,714
|
120,008
|
||||
|
Effect of foreign exchange rate changes
|
63
|
(204)
|
71
|
|||
|
Cash and cash equivalents at the end of the period
|
66,540
|
131,896
|
75,856
|
|||